Discovery of Versatile Short Linear Peptide-Based Checkpoint Inhibitors

Explorations in Global Health (ExGloH) is a division of Leidos Health engaged in identifying novel peptide scaffolds (microtides) with immune modulating properties. By screening diverse peptide libraries (e.g. microbiome) and using computational chemistry, we have identified linear peptides that bind and inhibit PD1, CTLA4 and LAG3. In mouse oncology and infectious disease models, the lead peptide LD01 with dual PD-1/CTLA4 antagonist expands vaccine-induced antigen-specific T cells, enhances anti-tumor activity and therapeutically rescues immune dysregulation. ExGloH seeks to out-license the use of microtides and establish new discovery partnerships for its platform.